Every Form 4 that CytomX Therapeutics, Inc. (CTMX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CTMX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CTMX filings page.
CytomX Therapeutics, Inc. granted Chief Legal Officer Alejandra Carvajal 450,000 stock options on August 3, 2026, with an exercise price of 3.1700 per share and expiration on August 2, 2036. The options vest 25% after one year from August 3, 2026, then monthly over four years, subject to continued service.
On the same date, Carvajal also received 100,000 restricted stock units (RSUs), each settling into one share of common stock upon vesting. These RSUs vest 25% annually each September 15, starting September 15, 2027, contingent on continued service. Following these awards, she holds 450,000 options and 100,000 RSUs directly.
CytomX Therapeutics director Charles S. Fuchs received a grant of stock options covering 118,000 shares of common stock, with an exercise price of $3.24 per share and an expiration date of July 23, 2036. 1/36th of the shares vest on each monthly anniversary starting July 24, 2026, so all options vest over three years, subject to his continued service.
CytomX Therapeutics director Su Zhen received a grant of stock options covering 59,000 shares of common stock. The options were awarded at an exercise price of $2.96 per share and are held directly. Following this grant, Su Zhen holds stock options for 59,000 shares.
According to the vesting terms, all 59,000 option shares will vest in full on the earlier of the first anniversary of the grant date or the date of CytomX’s 2027 annual stockholder meeting, assuming continuous service as a director through that vesting date.
CytomX Therapeutics director Matthew P. Young received a grant of stock options representing rights to buy 59,000 shares of common stock at an exercise price of $2.96 per share.
All 59,000 option shares will vest in full on the earlier of the first anniversary of the grant date or the 2027 Annual Meeting of CytomX stockholders, as long as he continues serving as a director until that vesting date.
CytomX Therapeutics director Mani Mohindru received a grant of 59,000 stock options for Common Stock. The options have an exercise price of $2.96 per share and expire on June 16, 2036. All 59,000 options vest in full on the earlier of the first anniversary of the grant date or the 2027 Annual Meeting of stockholders, subject to continuous service as a director.
CytomX Therapeutics, Inc. director James R. Meyers received a grant of stock options covering 59,000 shares of common stock. The options have an exercise price of $2.96 per share and expire on June 16, 2036.
According to the award terms, 100% of the options will vest on the earlier of the first anniversary of the grant date or the 2027 Annual Meeting of stockholders, assuming he continues to serve as a director through that date. Following this grant, he holds 59,000 derivative securities directly, reflecting a compensation-related award rather than an open‑market purchase.
CytomX Therapeutics director Halley E. Gilbert received a new stock option grant for 59,000 shares of common stock at an exercise price of $2.96 per share. This is a compensation-related award, not an open-market purchase or sale.
The option vests in full on the earlier of the first anniversary of the grant date or the date of CytomX’s 2027 annual stockholder meeting, assuming continuous service as a director through that date. Following this grant, Gilbert is reported as holding 59,000 stock options directly.
CytomX Therapeutics director Alan Ashworth received a grant of stock options covering 59,000 shares of common stock. The options have an exercise price of $2.96 per share and expire on June 16, 2036.
According to the terms, 100% of the shares subject to the option will vest on the earlier of the first anniversary of the grant date or the 2027 annual meeting of stockholders, assuming he continues to serve as a director through that date. Following this grant, he holds options for 59,000 shares directly.
CytomX Therapeutics, Inc. reported that director Elaine V. Jones received a stock option grant. She was awarded options to acquire 59,000 shares of common stock at an exercise price of $2.96 per share, giving her rights to buy shares at that price in the future.
After this grant, she holds 59,000 derivative securities linked to common stock. According to the terms, all 59,000 option shares will vest in full on the earlier of the first anniversary of the grant date or the date of the 2027 annual stockholder meeting, assuming she continues serving as a director until that vesting date.
CytomX Therapeutics Chief Financial Officer Christopher Ogden reported an open-market sale of 1,624 shares of common stock on June 15, 2026 at an average price of $3.05 per share. According to the disclosure, the shares were sold solely to satisfy tax and other government withholding obligations arising from the vesting of restricted stock units, so the transaction reflects a tax-related event rather than a discretionary portfolio move.
After this sale, Ogden holds a total of 295,324 shares of CytomX Therapeutics common stock, including 167,249 restricted stock units that will convert into shares as they vest over time. The sale represents a small portion of his overall direct equity position, indicating that he retains substantial exposure to the company’s stock following this routine tax-withholding transaction.
CytomX Therapeutics Chief Medical Officer Yu‑Waye Chu reported an open-market sale of 21,279 shares of common stock at $6.423 per share. According to the filing, the shares were sold solely to cover tax and other government withholding obligations tied to vesting restricted stock units. After this transaction, Chu directly holds 189,446 shares, which includes 149,833 RSUs that may settle in stock as they vest.
CytomX Therapeutics CEO Sean A. McCarthy reported a tax-driven share sale. He sold 118,969 shares of common stock on March 17, 2026 at an average price of $6.423 per share, solely to satisfy tax and other government withholding obligations linked to vesting restricted stock units.
After this transaction, he directly holds 1,078,922 common shares, which include 457,500 RSUs, and indirectly holds 93,158 shares through the Sean A. McCarthy 2018 Trust, where he serves as trustee. The filing shows no remaining derivative securities such as stock options or warrants.
CytomX Therapeutics, Inc. executive Marcia Belvin, SVP and Chief Scientific Officer, reported an open-market sale of 31,492 shares of common stock on March 17, 2026 at $6.423 per share. The sale was made solely to satisfy tax or other government withholding obligations tied to vesting restricted stock units (RSUs).
After this transaction, Belvin directly holds 300,760 shares of common stock, which includes 135,833 RSUs. This filing reflects a compensation-related tax obligation rather than a discretionary portfolio trade.
CytomX Therapeutics, Inc. Chief Financial Officer Christopher Ogden sold 19,323 shares of common stock at an average price of $6.423 per share. The sale was made solely to satisfy tax and other government withholding obligations related to vesting restricted stock units. After this transaction, he directly holds 296,948 shares of common stock, which includes 173,082 restricted stock units.
CytomX Therapeutics granted equity awards to its Chief Business Officer, Rachael Lester, effective February 2, 2026. The filing shows an award of 20,000 shares of common stock, which the footnotes explain are restricted stock units (RSUs) that convert into one share each as they vest. One-third of these RSUs vest annually on March 15, starting in 2027, as long as she continues as a service provider.
The company also granted a stock option for 50,000 shares at an exercise price of $6.09 per share. This option vests in equal monthly installments over four years from February 2, 2026, becoming fully vested on the fourth anniversary if her service continues. In addition, she received 50,000 Performance Stock Units (PSUs), each representing a right to one share of common stock. One-third of the PSUs vest upon the achievement of each of three clinical milestones, again conditioned on continued service.
CytomX Therapeutics Chief Medical Officer Yu-Waye Chu reported new equity awards. On February 2, 2026, Chu received 75,000 shares of Common Stock in the form of restricted stock units at a price of $0 per share. These RSUs convert into one share of Common Stock per unit, with one-third vesting each year on March 15, starting on March 15, 2027, subject to continued service.
On the same date, Chu was granted a stock option for 300,000 shares of Common Stock at an exercise price of $6.09 per share. One forty-eighth of the option vests monthly starting from February 2, 2026, becoming fully vested on the fourth anniversary of that date, also subject to continued service. After these transactions, Chu beneficially owns 210,725 shares of Common Stock, including 206,000 RSUs.
CytomX Therapeutics reported new equity awards for SVP and Chief Scientific Officer Marcia Belvin. On February 2, 2026 she received 60,000 restricted stock units of common stock at a price of $0, increasing her directly held common stock to 332,252 shares, including 218,958 RSUs.
She was also granted a stock option for 250,000 shares of common stock with a $6.09 exercise price. The option vests in equal monthly installments over four years starting from February 2, 2026, and the RSUs vest in three equal annual installments beginning March 15, 2027, subject to continued service.
CytomX Therapeutics reported new equity awards for its Chief Financial Officer, Christopher Ogden. On February 2, 2026, he acquired a stock option covering 325,000 shares of common stock at an exercise price of $6.09 per share and a grant of 90,000 restricted stock units (RSUs) at no cost.
The option vests in equal monthly installments over four years starting from February 2, 2026, becoming fully vested on the fourth anniversary, subject to continued service. The RSUs vest in three equal annual installments each March 15, beginning March 15, 2027, also subject to his continued service.
CytomX Therapeutics CEO Sean A. McCarthy reported new equity awards. On February 2, 2026, he was granted stock options for 980,000 shares of Common Stock with a $6.09 exercise price, vesting in equal monthly installments over four years from that date and expiring on February 1, 2036.
He also acquired 210,000 shares of Common Stock at $0 as restricted stock units, which vest in three equal annual installments each March 15, starting March 15, 2027, contingent on continued service. After these grants, he beneficially owns 1,197,891 shares directly, including 698,750 RSUs, plus 93,158 shares held indirectly by the Sean A. McCarthy 2018 Trust, for which he serves as trustee.
CytomX Therapeutics (CTMX) reported an insider transaction by its CEO and Director, Sean A. McCarthy. On 11/06/2025, he sold 101,793 shares of Class A common stock pursuant to a Rule 10b5-1 trading plan adopted on August 27, 2024.
The sale was executed at a weighted average price of $4.5377, with trades occurring between $4.50 and $4.62. Following this transaction, he beneficially owns 987,891 shares directly, which include 488,750 restricted stock units. He also holds 93,158 shares indirectly through the Sean A. McCarthy 2018 Trust, where he is trustee.
CytomX Therapeutics (CTMX) filed a Form 4 reporting a stock option grant to its Chief Business Officer, Rachael Lester. The award covers 650,000 options to buy common stock at an exercise price of $3.74 per share, granted on 10/20/2025.
Per the vesting terms, 25% of the shares vest on the one-year anniversary of October 20, 2025, with the remainder vesting in equal monthly installments so that the grant is fully vested on the fourth anniversary. The options expire on 10/19/2035. Ownership is reported as Direct (D).
CytomX Therapeutics insider grant to Chief Medical Officer
Yu-Waye Chu, Chief Medical Officer of CytomX Therapeutics, acquired equity awards on 09/26/2025 consisting of a stock option to purchase 87,500 shares of common stock at an exercise price of $2.90 and 43,750 Performance Stock Units (PSUs), each PSU representing one contingent share. The option vests monthly at 1/48th beginning on the Vesting Commencement Date of 09/26/2025 and becomes fully vested on the fourth anniversary if the reporting person remains in service. The PSUs vest in three tranches, with 1/3 vesting upon achievement of each of three specified clinical milestones, subject to continued service. All reported holdings are direct.
CytomX Therapeutics (CTMX) Chief Financial Officer Christopher Ogden reported option and performance‑unit awards on Sept 26, 2025. He was granted a stock option to buy 78,250 shares at a $2.90 exercise price that vests monthly over four years beginning Sept 26, 2025, and 39,150 Performance Stock Units (PSUs) that vest in three tranches tied to clinical milestones, each PSU convertible into one share on vesting. Following these awards, Mr. Ogden beneficially owns 78,250 option shares and 39,150 PSUs, all held directly. The option expires Sept 25, 2035. The filing is signed Sept 30, 2025.
Marcia Belvin, SVP and Chief Scientific Officer of CytomX Therapeutics (CTMX), was granted equity awards on 09/26/2025. The filing reports a stock option to purchase 36,300 shares with an exercise price of $2.90 and 18,150 Performance Stock Units (PSUs) that convert to one share each upon vesting. The option vests monthly at 1/48th beginning on the Vesting Commencement Date of 09/26/2025, reaching full vesting on the fourth anniversary if service continues. The PSUs vest in three equal tranches upon achievement of specified clinical milestones, subject to continued service. The Form 4 was signed by an attorney-in-fact on 09/30/2025.